Why the study?
Cardiovascular disease is common in cancer patients due to preexisting risk factors or anticancer therapies, prompting the need for multidisciplinary approaches aligned with recent ESC Cardio-Oncology Guidelines.
Describes the development and organization of a multidisciplinary Cardio-Oncology program to prevent and manage cardiovascular complications of cancer therapies, aligned with recent ESC guidelines.
May guide local cardio-oncology program development; leaves open prospective outcome validation.
Cardiovascular disease is a common problem in cancer patients that is becoming more widely recognized. This may be a consequence of prior cardiovascular risk factors but could also be secondary to the anticancer treatments. With the goal of offering a multidisciplinary approach to guaranteeing optimal cancer therapy and the early detection of related cardiac diseases, and in light of the recent ESC Cardio-Oncology Guideline recommendations, we developed a Cardio-Oncology unit devoted to the prevention and management of these specific complications. This document brings together important aspects to consider for the development and organization of a Cardio-Oncology program through our own experience and the current evidence.
No takes yet. Share an insight, caveat, or question.
Pons-Riverola et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: